FDA cannot keep track of medical devices and their manufacturers
This article was originally published in Clinica
The US General Accounting Office (GAO) has identified "several weaknesses" in the FDA's regulation of medical device tracking which it says threatens the agency's ability to adequately protect the public.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.